Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 6;11(7):1238.
doi: 10.3390/cells11071238.

Molecular Markers of Pediatric Solid Tumors-Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions

Joanna Trubicka  1 , Wiesława Grajkowska  1 , Bożenna Dembowska-Bagińska  2
Affiliations
Review

Molecular Markers of Pediatric Solid Tumors-Diagnosis, Optimizing Treatments, and Determining Susceptibility: Current State and Future Directions

Joanna Trubicka et al. Cells. .

Abstract

Advances in molecular technologies, from genomics and transcriptomics to epigenetics, are providing unprecedented insight into the molecular landscape of pediatric tumors. Multi-omics approaches provide an opportunity to identify a wide spectrum of molecular alterations that account for the initiation of the neoplastic process in children, response to treatment and disease progression. The detection of molecular markers is crucial to assist clinicians in accurate tumor diagnosis, risk stratification, disease subtyping, prediction of treatment response, and surveillance, allowing also for personalized cancer management. This review summarizes the most recent developments in genomics research and their relevance to the field of pediatric oncology with the aim of generating an overview of the most important, from the clinical perspective, molecular markers for pediatric solid tumors. We present an overview of the molecular markers selected based on therapeutic protocols, guidelines from international committees and scientific societies, and published data.

Keywords: molecular markers; molecular target for therapy; pediatric solid tumors; prognostic and predictive marker.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interest.

References

    1. [(accessed on 27 February 2022)]; Available online: https://seer.cancer.gov/iccc/iccc-iarc-2017.html#fn.
    1. Steliarova-Foucher E., Colombet M., Ries L.A.G., Moreno F., Dolya A., Bray F., Hesseling P., Shin H.Y., Stiller C.A., IICC-3 Contributors International incidence of childhood cancer, 2001–2010: A population-based registry study. Lancet Oncol. 2017;18:719–731. doi: 10.1016/S1470-2045(17)30186-9. - DOI - PMC - PubMed
    1. Styczyński J., Balwierz W., Dembowska-Bagińska B., Kazanowska B., Wachowiak J., Matysiak M., Klukowska A., Krawczuk-Rybak M., Adamkiewicz-Drożyńska E., Młynarski W.M. Paediatric oncology and haematology in Poland: Position paper. Pediatr. Pol. 2018;93:451–461. doi: 10.5114/polp.2018.82653. - DOI
    1. Abeloff M.D., Armitage J.O., Niederhuber J.E., Kastan M.B., McKenna W.G. Abeloff’s Clinical Oncology E-Book. Elsevier Health Sciences; Amsterdam, The Netherlands: 2008.
    1. WHO Classification of Tumours Editorial Board . World Health Organization Classification of Tumours of the Central Nervous System. 5th ed. International Agency for Research on Cancer; Lyon, France: 2021.

Publication types